Compare Expensify Inc (EXFY) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Expensify Inc trades at $2.44 (market cap $222.95M), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 4.4× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| EXFY | MRVI | |
|---|---|---|
Market Cap | $222.95M | $972.90M |
Volume | 293,722 | 4,325,710 |
Sector | Technology | Health |
52-Week High | $2.72 | $9.00 |
52-Week Low | $0.75 | $2.83 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | $162.57M | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.45, showing modest daily gains of 0.41%. The stock exhibits a bullish technical signal with strong moving average support. Fundamentally, the company maintains solid revenue around $142M but faces profitability challenges with negative net margins. Recent quarterly earnings show mixed results with two beats and one miss. Analyst sentiment leans positive with a 50% buy rating and $13.75 consensus price target, representing significant upside potential from current levels.
EXFY presents a high-risk, high-reward opportunity with substantial analyst upside but persistent profitability concerns. The company's expansion into European markets and AI integrations provide growth catalysts, though negative earnings and cash flow volatility remain key risks. Investors should weigh the significant price target premium against the company's ongoing transition to profitability.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
